RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+2.78%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1.04B
AUM Growth
+$1.04B
(-1.3%)
Cap. Flow
+$11.3M
Cap. Flow
% of AUM
1.09%
Top 10 Holdings %
Top 10 Hldgs %
35.44%
Holding
98
New
14
Increased
36
Reduced
31
Closed
5
Top Buys
| 1 |
UnitedHealth
UNH
|
$33M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$10.5M |
| 3 |
Danaher
DHR
|
$9.37M |
| 4 |
Edwards Lifesciences
EW
|
$9.01M |
| 5 |
Elevance Health
ELV
|
$8.83M |
Top Sells
| 1 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$20.8M |
| 2 |
Cigna
CI
|
$20.8M |
| 3 |
Tenet Healthcare
THC
|
$20.1M |
| 4 |
Medtronic
MDT
|
$9.21M |
| 5 |
Natera
NTRA
|
$8.99M |
Sector Composition
| 1 | Healthcare | 99.92% |
| 2 | Industrials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Dynavax Technologies
DVAX
$1.19B
| $13.8M | 1.33% |
1,232,361
+75,000
| +6% | +$842K |
|
27
Align Technology
ALGN
$9.59B
| $13.6M | 1.31% |
56,500
+6,500
| +13% | +$1.57M |
|
28
Thermo Fisher Scientific
TMO
$183B
| $13.3M | 1.27% |
24,000
+11,000
| +85% | +$6.08M |
|
29
DexCom
DXCM
$30.9B
| $13.3M | 1.27% |
117,000
-21,500
| -16% | -$2.44M |
|
30
Centene
CNC
$14.8B
| $13.2M | 1.26% |
198,482
+69,482
| +54% | +$4.61M |
|
31
Alignment Healthcare
ALHC
$3.23B
| $12.8M | 1.23% |
1,641,448
-381,288
| -19% | -$2.98M |
|
32
Jazz Pharmaceuticals
JAZZ
$7.99B
| $12.2M | 1.17% |
114,000
-32,729
| -22% | -$3.49M |
|
|
33
Danaher
DHR
$143B
| $12.1M | 1.16% |
48,500
+37,500
| +341% | +$9.37M |
|
34
Cencora
COR
$57.2B
| $11.6M | 1.11% |
51,500
+9,000
| +21% | +$2.03M |
|
35
Cytokinetics
CYTK
$5.98B
| $10.7M | 1.03% |
197,515
| – | – |
|
36
Neurocrine Biosciences
NBIX
$13.5B
| $10.4M | 1% |
75,555
+16,555
| +28% | +$2.28M |
|
37
Axsome Therapeutics
AXSM
$6.09B
| $10.3M | 0.99% |
127,600
-16,000
| -11% | -$1.29M |
|
|
ITCI
38
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $9.73M | 0.93% |
142,000
+4,500
| +3% | +$308K |
|
39
Insulet
PODD
$24.2B
| $9.38M | 0.9% |
46,500
+11,750
| +34% | +$2.37M |
|
|
40
Edwards Lifesciences
EW
$47.7B
| $9.01M | 0.86% |
+97,500
| New | +$9.01M |
|
41
Madrigal Pharmaceuticals
MDGL
$9.7B
| $7.42M | 0.71% |
26,500
-10,000
| -27% | -$2.8M |
|
42
Iovance Biotherapeutics
IOVA
$800M
| $7.38M | 0.71% |
920,000
-35,000
| -4% | -$281K |
|
43
Charles River Laboratories
CRL
$7.99B
| $7.02M | 0.67% |
34,000
+21,300
| +168% | +$4.4M |
|
44
Insmed
INSM
$30.3B
| $6.67M | 0.64% |
+99,513
| New | +$6.67M |
|
45
IQVIA
IQV
$31.4B
| $6.55M | 0.63% |
31,000
| – | – |
|
46
Nuvalent
NUVL
$5.74B
| $6.28M | 0.6% |
82,750
-4,750
| -5% | -$360K |
|
47
Ionis Pharmaceuticals
IONS
$9.64B
| $6.2M | 0.59% |
+130,000
| New | +$6.2M |
|
48
Exact Sciences
EXAS
$9.33B
| $6.13M | 0.59% |
145,000
+2,000
| +1% | +$84.5K |
|
49
Stryker
SYK
$149B
| $6.12M | 0.59% |
18,000
+10,000
| +125% | +$3.4M |
|
50
Arvinas
ARVN
$580M
| $6.12M | 0.59% |
230,000
+60,000
| +35% | +$1.6M |
|